Augmenix Partners with Us TOO International to Stream Live Webcast and Q & A on Prostate Cancer Radiation Therapy
Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, together with Us TOO International, a nonprofit organization committed to improving the lives of those affected by prostate cancer, will hold a live webcast for prostate cancer patients and their caregivers on Monday, October 2, from 7:15 pm – 9:00 pm EST.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170928005968/en/
SpaceOAR separates the prostate and rectum during radiation treatment (Graphic: Business Wire)
The event will feature a didactic presentation from renowned radiation oncologist Daniel B. Fried, MD, MPH, PhD, who practices at the Gibbs Cancer Center and Research Institute in Greenville, S.C. He will provide relevant clinical information on radiation therapy as a viable treatment for prostate cancer, and discuss the quality of life benefits associated with the utilization of SpaceOAR® Hydrogel as an adjunctive therapy in protecting the rectum in men undergoing this form of treatment. The session will also include an opportunity for webcast attendees to submit questions for Dr. Fried through an online chat.
“More than 160,000 men will be diagnosed with prostate cancer in 2017 and we’re on a mission to help educate those affected so they’re empowered to make informed decisions on all aspects of the disease,” said Chuck Strand, CEO, Us TOO International. “We look forward to partnering with Augmenix on this special educational event. With the company’s support, we are able live stream the content to reach more men and their families throughout the country who are battling prostate cancer.”
The webcast will be live-streamed from an Us TOO support group meeting, which will take place at the Fellowship Greenville Church in Greer, S.C. The event and webcast participation is free of charge to anyone who registers. For registration information, visit bit.ly/2hwEulg. After the group meeting, the webcast recording will be archived for viewing at http://www.ustoo.org/ustoo-video.
“If detected early, prostate cancer is often treatable and knowledge of treatment options can lead to optimal outcomes,” said John Pedersen, CEO, Augmenix. “We are privileged to partner with Us TOO on patient-centric activities that aim to educate, empower and support these men and their families.”
To find a local Us TOO International support group, visit http://www.ustoo.org/Support-Group-Near-You. For more information on SpaceOAR hydrogel, visit www.SpaceOAR.com.
ABOUT AUGMENIX, INC.
Augmenix, Inc. is a privately held U.S.
company based in the Boston, Massachusetts area focused on the
development and commercialization of radiation oncology products using
its proprietary hydrogel technology. Focusing initially on protection
during prostate radiation therapy, Augmenix next-generation products
will address spacing and marking applications throughout the body to
improve radiotherapy and interventional oncology procedure outcomes. The
company’s lead product, SpaceOAR System, is FDA cleared and is currently
being used in the majority of leading cancer centers in the United
States. It is also CE marked, approved in Australia and Japan, and
licensed in Canada. SpaceOAR is a registered trademark of Augmenix, Inc.
More information about Augmenix and the SpaceOAR hydrogel can be found
at http://www.Augmenix.com.
ABOUT SPACEOAR® HYDROGEL
Radiation therapy in the treatment
of prostate cancer can cause unintended radiation injury to adjacent
healthy tissue (organs at risk). This injury can lead to a range of
bowel, urinary and sexual symptoms that can affect patient health and
quality of life during radiotherapy, and for years afterward. In recent
years, radiation oncologists have considered use of “spacing” techniques
to reduce the risk of radiation injury to surrounding tissue during
radiotherapy. SpaceOAR hydrogel is intended to temporarily position the
anterior rectal wall away from the prostate during radiotherapy for
prostate cancer and in creating this space it is the intent of SpaceOAR
hydrogel to reduce the radiation dose delivered to the anterior rectum.
The SpaceOAR hydrogel is injected as a liquid into the space between the
prostate and rectum where it pushes the structures apart and then
solidifies into a soft hydrogel. The hydrogel remains stable for three
months during radiation therapy then liquefies and is completely
absorbed by the body. See the Instructions for Use for complete
information on potential risks, warnings and precautions.
ABOUT US TOO INTERNATIONAL
Us TOO International is a
nonprofit that serves the prostate cancer community by providing
educational materials and resources at no charge. Established in 1990,
the organization was founded by—and continues to be governed by—people
directly affected by prostate cancer. The mission of Us TOO is to
provide hope and improve the lives of those affected by prostate cancer
through support, education and advocacy/awareness. Us TOO currently
maintains more than 200 support groups throughout the U.S. and abroad
that also help men and their spouses/partners and families make informed
decisions about prostate cancer detection, treatment options and related
side effects. For more information, visit http://www.ustoo.org/.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170928005968/en/
AUGMENIX, INC.
EILEEN GARDNER, RN, 781-902-1625
EGARDNER@AUGMENIX.COM
or
US
TOO INTERNATIONAL
TIM MIX, 630-795-1002
COMMUNICATIONS MANAGER
TIMOTHYM@USTOO.ORG
